High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis

Table 1 Profiles of AMAs in 348 screened women

	n	%
Anti-M2	8	2.3
Anti-M4	12	3.4
Anti-M9	5	1.4
Anti-M2+Anti-M4	5	1.4
Any AMA	30	8.6

Table 2 Serum concentrations of different types of AMAs in women with positive (at least one type of AMAs present) or negative AMAs (mean±SE)

	Qualitative AMAs		P
	Positive	Negative
Anti-M2 (RU/mL)	378.1 ± 96.8	6.1 ± 1.3	3 × 10–15
Anti-M4 (RU/mL)	140.5 ± 27.7	18.1 ± 1.9	2 × 10–17
Anti-M9 (RU/mL)	112.5 ± 25.9	35.8 ± 3.8	2 × 10–7

Table 3 Correlation between AMA concentration and biochemical indices of liver injury and Mayo risk score in asymptomatic AMA positive women

	Anti-M2	Anti-M4	Anti-M9
Bilirubin	0.410a	0.339	0.011
Albumin	–0.500a	–0.406a	0.119
PT	0.321	0.514a	0.002
Mayo risk score	0.415a	0.572a	–0.088

^aP<0.05.

Table 4 Serum concentrations of different types of AMAs in patients with pPBC or nPBC during 5-year follow-up (mean±SE)

	pPBC	nPBC	P
Anti-M2 (RU/mL)	199 ± 48	265 ± 81	6×10–12
Anti-M4 (RU/mL)	474 ± 149	103 ± 17	0.09
Anti-M9 (RU/mL)	49 ± 15	120 ± 28	0.03

Table 5 Serum concentrations of bilirubin and albumin, PT, and MRF value in patients with pPBC or nPBC during 5-year follow-up (mean±SE)

	pPBC	nPBC	P
Bilirubin (mg%)	2.2 ± 1.1	0.76 ± 0.1	0.241
Albumin (g%)	2.7 ± 0.2	3.5 ± 0.1	0.027
PT (s)	17.0 ± 0.8	14.7 ± 0.2	0.056
Mayo risk score	7.2 ± 0.8	4.8 ± 0.2	0.058